Insider · CIK 0001901565
Sireesh Appajosyula
Files at HEPA (Hepion Pharmaceuticals, Inc.), CNTN (Canton Strategic Holdings, Inc.). First filing Nov 13, 2024, latest Apr 27, 2026.
Sireesh Appajosyula files SEC Form 4 as COO, director and CEO at CNTN (Canton Strategic Holdings, Inc.), and also at HEPA (Hepion Pharmaceuticals, Inc.). Since Nov 13, 2024, Sireesh Appajosyula has reported 3 open-market buys worth $151k and 0 open-market sells worth $0, the latest filed on Apr 27, 2026.
A track record needs three past buys with six months of prices behind them; Sireesh Appajosyula has 0, so none is measured yet.
The newest scored trade: bought $50k of HEPA on Apr 21, 2026, filed Apr 27, 2026, scored 53 (moderate). In the last 12 months: 1 buy worth $50k and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
CNTN: Canton Strategic Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
HEPA: Hepion Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Hepion Pharmaceuticals, Inc. | $50k 1,250,000 shares | - | +14% from low-90% from high | |
| 67Notable | Canton Strategic Holdings, Inc. | $91k 61,496 shares | +1824% | +28% from low-61% from high | |
| 30Weak | CNTNbuy Canton Strategic Holdings, Inc. | $10k 5,000 shares | +87% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | HEPA Hepion Pharmaceuticals, Inc. | POpen-market purchase Common Stock, par value $0.0001 per share | +1,250,000 | $0.04 | $50k | 1,250,000 | Apr 27, 2026 |
| Nov 3, 2025 | CNTN Canton Strategic Holdings, Inc. | AGrant or award Stock Optionderivative | +20,000 | $0.00 | $0 | 225,962 | Nov 5, 2025 |
| Aug 4, 2025 | CNTN Canton Strategic Holdings, Inc. | AGrant or award Stock Optionderivative | +90,000 | $0.00 | $0 | 205,962 | Aug 6, 2025 |
| Jun 20, 2025 | CNTN Canton Strategic Holdings, Inc. | POpen-market purchase Common Stock | +60,806 | $1.48 | $90k | 64,178 | Jun 23, 2025 |
| Jun 20, 2025 | CNTN Canton Strategic Holdings, Inc. | POpen-market purchase Common Stock | +690 | $1.42 | $980 | 64,868 | Jun 23, 2025 |
| Jan 13, 2025 | CNTN Canton Strategic Holdings, Inc. | AGrant or award Options (right to buy)derivative | +52,875 | $0.00 | $0 | 115,962 | Jan 14, 2025 |
| Nov 13, 2024 | CNTN Canton Strategic Holdings, Inc. | POpen-market purchase Common Stock | +5,000 | $2.02 | $10k | 10,758 | Nov 13, 2024 |
Questions about Sireesh Appajosyula
Answered from the filings on this page, as of the latest one.
Is Sireesh Appajosyula buying or selling?
In the last 12 months Sireesh Appajosyula reported 1 open-market buy worth $50k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $50k of HEPA on Apr 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Sireesh Appajosyula's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sireesh Appajosyula has 0.
Where does Sireesh Appajosyula file Form 4?
Sireesh Appajosyula has filed Form 4 at CNTN (Canton Strategic Holdings, Inc.) as CEO; HEPA (Hepion Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.